In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $3.96 in the prior trading day, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $4.15, up 4.80%. In other words, the price has increased by $4.80 from its previous closing price. On the day, 1.05 million shares were traded. IRWD stock price reached its highest trading level at $4.36 during the session, while it also had its lowest trading level at $4.065.
Ratios:
Our goal is to gain a better understanding of IRWD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.53. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 3.92.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on September 09, 2024, initiated with a Market Perform rating and assigned the stock a target price of $5.
On August 08, 2024, CapitalOne Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $12 to $4.
On January 17, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $21.Craig Hallum initiated its Buy rating on January 17, 2024, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 12 ’24 when John Minardo sold 9,910 shares for $4.27 per share. The transaction valued at 42,316 led to the insider holds 284,661 shares of the business.
Silver Ronald sold 3,107 shares of IRWD for $13,267 on Aug 12 ’24. The Principal Accounting Officer now owns 158,370 shares after completing the transaction at $4.27 per share. On Aug 12 ’24, another insider, John Minardo, who serves as the Officer of the company, bought 11,726 shares for $4.05 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 666265920 and an Enterprise Value of 1197648896. As of this moment, Ironwood’s Price-to-Earnings (P/E) ratio for their current fiscal year is 96.06, and their Forward P/E ratio for the next fiscal year is 12.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.65. Its current Enterprise Value per Revenue stands at 2.99 whereas that against EBITDA is 9.901.
Stock Price History:
Over the past 52 weeks, IRWD has reached a high of $15.70, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -5.77%, while the 200-Day Moving Average is calculated to be -45.19%.
Shares Statistics:
The stock has traded on average 1.86M shares per day over the past 3-months and 954660 shares per day over the last 10 days, according to various share statistics. A total of 156.35M shares are outstanding, with a floating share count of 155.59M. Insiders hold about 2.60% of the company’s shares, while institutions hold 108.47% stake in the company. Shares short for IRWD as of 1728950400 were 11931395 with a Short Ratio of 6.43, compared to 1726185600 on 11614582. Therefore, it implies a Short% of Shares Outstanding of 11931395 and a Short% of Float of 14.46.
Earnings Estimates
The current rating of Ironwood Pharmaceuticals Inc (IRWD) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.11, with high estimates of $0.36 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.73 and $0.1 for the fiscal current year, implying an average EPS of $0.24. EPS for the following year is $0.39, with 6.0 analysts recommending between $0.7 and $0.2.
Revenue Estimates
7 analysts predict $90.86M in revenue for the current quarter. It ranges from a high estimate of $94.3M to a low estimate of $85.3M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $113.74MFor the next quarter, 7 analysts are estimating revenue of $95.65M. There is a high estimate of $101.52M for the next quarter, whereas the lowest estimate is $89.5M.
A total of 7 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $363.49M, while the lowest revenue estimate was $350.3M, resulting in an average revenue estimate of $356.2M. In the same quarter a year ago, actual revenue was $442.74MBased on 7 analysts’ estimates, the company’s revenue will be $359.91M in the next fiscal year. The high estimate is $407.9M and the low estimate is $290M.
